reports
WINFARM : Croissance de +9,4% du chiffre d’affaires du T2 2024.
WINFARM : Croissance de +9,4% du chiffre d’affaires du T2 2024. COMMUNIQUE DE PRESSE Loudéac, le 4 septembre 2024 Croissance de +9,4% du chiffre d’affaires du T2 2024 AgroFourniture : Retour de la croissance AgroProduction : forte progression des ventes sur toutes les géographies WINFARM (ISIN : FR0014000P11 – mnémonique : ALWF), 1er groupe français proposant un ensemble de prestations de conseil, de service, et de vente à distance de produits et de solutions au monde agricole et à l’élevage, annonce ce jour la publication du chiffre d’affaires du 2ème trimestre 2024. En millions d’...
Pharming Group to participate in September investor conferences
Pharming Group to participate in September investor conferences Leiden, the Netherlands, September 4, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the U.S. in the month of September: 2024 Wells Fargo Healthcare Conference, Boston, September 4-6Sijmen de Vries, Chief Executive Officer, will participate in a fireside chat question and answer session on Friday, September 6 at 08:45 AM ET/14:45 CET. A live webcast and replay of the presentation will be available i...
Pharming Group NV: 1 director
A director at Pharming Group NV sold 187,700 shares at 0.740EUR and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Pharming Group reports second quarter and first half 2024 financial re...
Pharming Group reports second quarter and first half 2024 financial results and provides business update Second quarter 2024 total revenues increased by 35% to US$74.1 million, compared to the second quarter 2023, driven by strong RUCONEST® and Joenja® revenue growthRUCONEST® second quarter revenue increased by 23% to US$63.0 million, compared to the second quarter 2023Joenja® (leniolisib) second quarter revenue increased by 16% to US$11.1 million, compared to the first quarter 2024 First half total revenues increased by 33% to US$129.7 million, compared to the first half 2023On track for 2...
- Baptiste Salaville
- Fehmi Ben Naamane
- Jean-Baptiste Rouphael
- Marc Lavaud
- Oddo Sustainability Team
ODDO BHF Small & MIDCAP MORNING NEWS - 23/07/2024
Oerlikon, leader in attractive niche markets with technology entry barriers, is about to enter the final chapter of its group transition into a Surface Solutions pure play via the planned separation of Polymer Processing Solutions (OPP) in the next 12-36 months. After the strong performance YTD, we are seeing no further significant upside from here for now. We are rating Oerlikon’s shares Neutral with a TP of CHF 5.2. - ...
DKSH DKSH HOLDING AG
WTB WHITBREAD PLC
IDL ID LOGISTICS GROUP
EXE EXEL INDUSTRIES SA
POM PLASTIC OMNIUM SE
ITP INTERPARFUMS
BEN BENETEAU SA
WHA WERELDHAVE N.V.
SHA SCHAEFFLER AG
DLG DE'LONGHI S.P.A.
CIE CIE AUTOMOTIVE S.A.
SHOT SCANDIC HOTELS GROUP
NVG NAVIGATOR COMPANY SA
MEL MELIA HOTELS INTERNATIONAL S.A.
NHH NH HOTEL GROUP SA
ALM ALMIRALL SA
IHG INTERCONTINENTAL HOTELS GROUP PLC
DSC1 DUTCH STAR C SHAR
VTSC VITESCO TECHNOLOGIES GRP AG
- Baptiste Salaville
- Fehmi Ben Naamane
- Jean-Baptiste Rouphael
- Marc Lavaud
- Oddo Sustainability Team
ODDO BHF Small & MIDCAP MORNING NEWS - 07/23/2024
Oerlikon, leader in attractive niche markets with technology entry barriers, is about to enter the final chapter of its group transition into a Surface Solutions pure play via the planned separation of Polymer Processing Solutions (OPP) in the next 12-36 months. After the strong performance YTD, we are seeing no further significant upside from here for now. We are rating Oerlikon’s shares Neutral with a TP of CHF 5.2. - ...
DKSH DKSH HOLDING AG
WTB WHITBREAD PLC
IDL ID LOGISTICS GROUP
EXE EXEL INDUSTRIES SA
POM PLASTIC OMNIUM SE
ITP INTERPARFUMS
BEN BENETEAU SA
WHA WERELDHAVE N.V.
SHA SCHAEFFLER AG
DLG DE'LONGHI S.P.A.
CIE CIE AUTOMOTIVE S.A.
SHOT SCANDIC HOTELS GROUP
NVG NAVIGATOR COMPANY SA
MEL MELIA HOTELS INTERNATIONAL S.A.
NHH NH HOTEL GROUP SA
ALM ALMIRALL SA
IHG INTERCONTINENTAL HOTELS GROUP PLC
DSC1 DUTCH STAR C SHAR
VTSC VITESCO TECHNOLOGIES GRP AG
- Christophe Chaput
Beneteau : A tougher context in the US. 2024 guidance lowered. Target ...
>H1 sales down 31.5% at € 556.6m, close to forecasts (€ 566.5m) - For H1 of its full-year 2024, the Bénéteau group reported sales of € 556.6m, a level close to our forecasts, as we had retained € 566.6m, (gap of -1.7%) as well as those of the consensus (€ 563m, gap -1.1%). Compared to last year, sales are down 31.5% (-25.1% for Q2 alone). Over the period, the group has been hit with an impact of around -€ 80m related to retailers’ desires to reduce their inventories, ...
- Christophe Chaput
Bénéteau : Un contexte plus difficile aux Etats-Unis. Guidance 2024 aj...
>Un CA S1 en baisse de 31.5% à 556.6 M€, proche des attentes (566.5 M€) - Pour le premier semestre de son exercice 2024, le groupe Bénéteau publie un chiffre d’affaires de 556.6 M€ soit un niveau proche de nos attentes puisque nous retenions 566.5 M€ (écart -1.7%) et également de celles du consensus (563 M€ ; écart -1.1%). Par rapport à l’année dernière, le CA recule de 31.5% (-25.1% pour le seul T2). Sur la période, le groupe subit un impact d’environ -80 M€ lié à la...
Pharming Group to report second quarter and first half 2024 financial ...
Pharming Group to report second quarter and first half 2024 financial results on August 1 Leiden, the Netherlands, July 18, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) second quarter and first half 2024 financial results, for the period ended June 30, on Thursday, August 1, 2024.Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on August 1, 2024. To participate in the conference call, please register in advance using the link below. Once registered, dial-in informa...
WINFARM : Bilan semestriel du contrat de liquidité.
WINFARM : Bilan semestriel du contrat de liquidité. COMMUNIQUE DE PRESSE Loudéac, 15 juillet 2024 Bilan semestriel du contrat de liquidité Au titre du contrat de liquidité confié par la société WINFARM au CREDIT INDUSTRIEL ET COMMERCIAL, à la date du 30 juin 2024, les moyens suivants figuraient au compte de liquidité : 3 549 titres13 529,75 € Au cours du 1er semestre 2024, il a été négocié un total de : Achat71 950 titres413 856,12 EUR1 022 transactionsVente73 109 titres416 987,33 EUR901 transactions Il est rappelé que lors du bilan semestriel du 31/12/2023, les moyens suivants figur...
WINFARM : Déclaration mensuelle du nombre d’actions et de droits de vo...
WINFARM : Déclaration mensuelle du nombre d’actions et de droits de votes. COMMUNIQUE DE PRESSE Loudéac, 15 juillet 2024 Déclaration mensuelle du nombre d’actions et de droits de votes Date d’arrêté : 30/06/2024 Article 223-16 du règlement général de l’AMF Actions du capital 2 001 695Droits de vote théoriques (1) 3 340 053 Actions privées de droits de vote Autodétention au nominatif (2) -Autodétention au porteur (3) 3 549Autres (4) - Droits de vote exerçables* 3 336 504* = (1) – [(2) + (3) + (4)] Prochaine publication :Chiffre d’affaires du 1er semestre 2024, ...
WINFARM : Descriptif du programme de rachat d'actions.
WINFARM : Descriptif du programme de rachat d'actions. COMMUNIQUE DE PRESSE Loudéac, 18 juin 2024 WINFARMSociété anonyme au capital de 2.001.695 €Siège social : Zone Industrielle de Très Le Bois - 22600 LoudéacR.C.S. Saint Brieuc 492 656 640(la « Société ») DESCRIPTIF DU PROGRAMME DE RACHAT D’ACTIONS Conformément aux dispositions (i) du règlement délégué n°2016/1052 complétant le règlement européen n°596/2014 par des normes techniques de réglementation concernant notamment les conditions applicables aux programmes de rachat d’actions ainsi que (ii) des articles 241-1 et suivants du ...
- Guy Sips
- Hilde Van Boxstael
- Thomas Vranken
- Wim Lewi
- Guy Sips
- Hilde Van Boxstael
- Lynn Hautekeete
- Thomas Vranken
- Wim Hoste
- Wim Lewi
Pharming Group to participate in June investor conferences
Pharming Group to participate in June investor conferences Leiden, the Netherlands, June 3, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the month of June: Jefferies Healthcare Conference, New York, USA, June 5-6, 2024Sijmen de Vries, Chief Executive Officer, will present on Wednesday, June 5 at 10:30EDT/16:30CEST. A live webcast and replay of the presentation will be available in the “Upcoming Events” and “News” sections of Pharming’s website. Oppenheimer Nove...
Pharming Group provides update on ongoing regulatory review of lenioli...
Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union Leiden, the Netherlands, May 30, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today an update on the ongoing review of its Marketing Authorisation Application (MAA) for leniolisib for the treatment of adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta syndrome (APDS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...
Mithra postpones its annual general meeting
Mithra postpones its annual general meeting Liege, Belgium, 28 May 2024 – 15:00 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, today announces that in the context of the monetization process and the uncertainties related thereto, Mithra postpones its Annual General Shareholders’ Meeting, , to a later date to be determined. Background Information: Mithra announced the launch of a comprehensive monetization process, exploring potential sales of selected assets, notably Estetra SRL, and potentially the entire business. Additionally, Mithra announced the en...
- Pierre Dinet (IDMidCaps)
Beneteau - Back to normal after a string of records
After 3 years of records thanks to an extremely buoyant yachting market at the end of Covid, 2024 marks the end of the euphoria.Demand is normalising, leading to dealers destocking, and as a result, sales and earnings in 2024 will fall sharply, after peaking in 2023.Beneteau, which is more exposed to small units, is more affected than Catana and Fountaine Pajot, which have an order book and customer advances. For the time being, Trigano is not seeing a drop in demand either.Despite the expected ...
Pharming Group reports on results of the 2024 Annual General Meeting o...
Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders Leiden, the Netherlands, May 21, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, all proposals were approved.The shareholders approved the proposals to reappoint Ms. Barbara Yanni (agenda item 4.a) and Mr. Mark Pykett (agenda item 4.b), upon binding recommendation of the Board of Directors, as Non-Executive Directors for a period of four years. In addition, the proposals for the adopti...
Pharming Group to participate in May investor conference
Pharming Group to participate in May investor conference Leiden, the Netherlands, May 20, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conference in the month of May: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, New York, May 20, 2024Michael Levitan, VP Investor Relations and Corporate Communications will present on Monday, May 20 at 09:30 EDT/15:30 CET. For more information about this conference, or to schedule a one-to-one meeting with Pharming’s man...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.